Abstract
MicroRNAs (miRNAs) have been studied in cutaneous T-cell lymphoma (CTCL) for more than 15 years, revealing oncogenic and tumor-suppressive networks, the JAK/STAT-miRNA signaling circuit, diagnostic classifiers, and therapeutic miRNA targeting (Cobomarsen, targeting miRNA-155). Yet, no miRNA diagnostic has reached clinical practice. We synthesize the CTCL miRNA literature and argue that translation has stalled as a result of 2 interrelated limitations-methodological and biological-including reliance on bulk-tissue profiling and the intrinsic miRNA biology, including modest regulation of multiple pathways. Future strategies encompassing single-cell and subclone profiling, targeted anti-miRNA delivery, multiomics integration, miRNA network remodeling, multicenter validation, and artificial intelligence-driven bioinformatics may herald a golden renaissance for miRNAs.
| Original language | English |
|---|---|
| Journal | Journal of investigative dermatology |
| DOIs | |
| Publication status | E-pub ahead of print - 01 Sept 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fields of science
- 301902 Immunology
- 302 Clinical Medicine
- 302011 Dermatology
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver